VRTX - Vertex Pharmaceuticals Incorporated
NEXT EARNINGS:
May 4, 2026
EPS Est: $4.53
|
Rev Est: $3.1B
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$545.08
DETAILS
HIGH:
$607.00
LOW:
$441.00
MEDIAN:
$551.50
CONSENSUS:
$545.08
UPSIDE:
11.83%
Market Cap:
123.81B
Volume:
1,331,342
Avg Volume:
1,460,781
52 Week Range:
362.5-519.68
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.32
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
6,100
IPO Date:
1991-07-24
EPS (TTM):
15.46
P/E Ratio:
29.32
Revenue (TTM):
12.07B
Total Assets:
26.14B
Total Debt:
3.88B
Cash & Equiv:
5.09B
Rev Growth (5Y):
14.2%
EPS Growth (5Y):
8.2%
FCF Growth (5Y):
1.3%
ROCE:
21.4%
Debt/Equity:
0.21
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-12 | $5.03 | $5.11 | -1.6% | $3.2B | $3.2B | +1.3% |
| 2025-11-03 | $4.80 | $4.57 | +5.0% | $3.1B | $3.1B | +0.6% |
| 2025-08-04 | $4.52 | $4.29 | +5.4% | $3.0B | $2.9B | +2.0% |
| 2025-05-05 | $4.06 | $4.25 | -4.5% | $2.8B | $2.9B | -3.2% |
| 2025-02-10 | $3.98 | $4.02 | -1.0% | $2.9B | $2.8B | +4.6% |
| 2024-11-04 | $4.38 | $4.14 | +5.8% | $2.8B | $2.7B | +3.2% |
| 2024-08-01 | $-12.83 | $-11.63 | -10.3% | $2.6B | $2.7B | -1.1% |
| 2024-05-06 | $4.76 | $4.06 | +17.2% | $2.7B | $2.6B | +4.1% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.07B | 11.02B | 9.87B | 8.93B | 7.57B | 6.21B | 4.16B | 3.05B | 2.49B | 1.70B | 1.03B | 580.41M |
| Net Income | 3.95B | (535.60M) | 3.62B | 3.32B | 2.34B | 2.71B | 1.18B | 2.10B | 263.48M | (112.05M) | (558.12M) | (738.55M) |
| EPS | 15.46 | -2.08 | 14.05 | 12.97 | 9.09 | 10.44 | 4.58 | 8.25 | 1.06 | -0.46 | -2.32 | -3.14 |
| Total Assets | 26.14B | 22.53B | 22.73B | 18.15B | 13.43B | 11.75B | 8.32B | 6.25B | 3.55B | 2.89B | 2.50B | 2.34B |
| Total Debt | 3.88B | 1.75B | 808.40M | 899.70M | 967.40M | 931.90M | 661.66M | 586.82M | 606.43M | 840.76M | 826.24M | 824.95M |
| Cash & Equivalents | 5.09B | 4.57B | 10.37B | 10.50B | 6.79B | 5.99B | 3.11B | 2.65B | 1.67B | 1.18B | 714.77M | 625.26M |
| Operating Cash Flow | 3.63B | (492.60M) | 3.54B | 4.13B | 2.64B | 3.25B | 1.57B | 1.27B | 844.94M | 236.10M | (365.43M) | (513.20M) |
| Free Cash Flow | 3.19B | (790.30M) | 3.28B | 3.93B | 2.41B | 2.99B | 1.49B | 1.17B | 585.52M | 179.54M | (410.73M) | (564.40M) |
| FCF per Share | 12.49 | -3.07 | 12.72 | 15.33 | 9.35 | 11.52 | 5.82 | 4.62 | 2.35 | 0.74 | -1.71 | -2.40 |
| Book Value | 18.67B | 16.41B | 17.58B | 13.91B | 10.10B | 8.69B | 6.09B | 4.44B | 2.03B | 1.16B | 939.97M | 1.08B |
| Cash & ST Investments | 6.61B | 6.12B | 11.22B | 10.78B | 7.52B | 6.66B | 3.81B | 3.17B | 2.09B | 1.43B | 1.04B | 1.39B |
| ROC Equity | 0.21 | -0.03 | 0.21 | 0.24 | 0.23 | 0.31 | 0.19 | 0.47 | 0.13 | -0.10 | -0.59 | -0.69 |